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Introduction	
Hormonal	contraceptives	are	the	most	widely	used	form	of	contraception	in	sub-Saharan	Africa	with	
12	million	women	using	an	injectable	form	(‘injectables’	or	IHC),[1]	and	uptake	of	IHC	has	been	
rapidly	increasing	over	the	last	two	decades	in	many	parts	of	the	world.[2]	
	
Some	high-quality	prospective	observational	studies	have	reported	a	statistically	significant	increase	
in	risk	of	HIV	acquisition	associated	with	IHC	use,[3-6]	but	others	have	not.[7-11]	Among	the	former,	
the	largest	risk	estimate	detected	was	a	two-fold	increase	in	HIV	acquisition	(odds	ratio	(OR)	=	2.19	
(95%	confidence	interval	(CI)	1.01-4.74)	in	a	recent	analysis	of	women	using	IHC	in	heterosexual	
serodiscordant	couples	[5];	the	other	studies	detected	point	estimates	of	1.48	(1.02-2.15),[4]	1.72	
(1.19-2.49)[6]	and	1.73	(1.28-2.34).[3]		Although	there	is	no	scientific	consensus	that	IHC	is	causally	
related	to	HIV	risk	in	women,	any	factor	found	to	increase	HIV	acquisition	is	potentially	important	
and	could	have	significant	public	health	implications.	In	countries	with	high	levels	of	IHC	use,	
increased	HIV	risk	could	have	a	substantial	effect	if	the	underlying	risk	for	HIV	acquisition	is	high.	If	
there	is	a	causal	relationship	between	the	two,	reductions	in	IHC	usage	in	such	areas	may	lead	to	a	
decrease	in	HIV	infections,	but	there	may	also	be	other	significant	consequences	of	the	reduced	
availability	of	effective	contraceptive	options	for	women.	For	example,	increases	in	unintended	
pregnancies	would	lead	to	a	number	of	adverse	outcomes	including	maternal	and	infant	deaths,	
particularly	in	regions	with	a	high	birth	rate	and	maternal	mortality.	Since	the	data	on	the	impact	of	
pregnancy	on	risk	of	HIV	acquisition	is	also	conflicting,	increases	in	unintended	pregnancy	may	also	
impact	the	HIV	risk.[8,	12-14]	Conversely,	there	may	be	some	countries	with	high	IHC	but	low	HIV	
incidence	and	maternal	mortality	where	the	potential	interaction	with	HIV	acquisition	will	have	little	
public	health	impact.		
	
A	technical	consultation	was	convened	by	the	WHO	in	January	2012	in	light	of	these	concerns.	After	
considering	the	totality	of	evidence,	the	panel	concluded	that	the	medical	eligibility	criteria	(MEC)	
for	IHC	use	should	remain	unchanged	from	the	current	rating,	and	added	a	strong	clarification	to	
note	that	women	using	progestogen-only	injectables	who	are	at	high	risk	of	HIV	should	be	strongly	
advised	to	also	always	use	male	or	female	condoms	and	other	preventive	measures.[15]	Increased	
uptake	of	interventions	such	as	ART	for	an	HIV-infected	partner	of	IHC	users	may	also	partially	offset	
any	increase	in	HIV	risk	for	these	women.		
		
In	this	analysis	we	model	the	global	public	health	implications	of	an	interaction	between	IHC	use	and	
HIV	risk	under	different	assumptions	about	the	true	effect	size.	We	use	country-level	outcomes	on	
HIV	infections,	live	births,	maternal	deaths,	and	HIV-related	deaths	to	explore	the	potential	
contribution	of	IHC	use	to	HIV	spread	and	the	overall	consequences	of	its	removal.	
Methods	
Distribution	of	injectable	hormonal	contraception	and	HIV	
First,	we	assessed	HIV	prevalence[16-20]	and	IHC	use[2]		for	each	country.	We	defined	IHC	use	as	
common	if	the	most	recent	estimate	of	current	IHC	use	is	within	the	top	quartile	of	all	countries	with	
available	data[2]	and	we	defined	HIV	prevalence	above	1%	as	high.	All	analyses	and	parameters	refer	
to	15-49	year-old	women.	
	
Effects	of	an	IHC–HIV	interaction	on	HIV	infections	per	year	
We	conducted	a	modelling	exercise	to	estimate	the	number	of	female	HIV	acquisitions	per	year	that	
could	be	attributed	to	IHC	use	under	two	hypothetical	scenarios.	First,	we	used	one	of	the	largest	
effect	sizes	estimated	for	the	IHC-HIV	interaction	to	date	(OR=2.19[5]);	this	is	the	higher	of	the	two	
estimates	from	the	Partners	in	Prevention	HSV/HIV	Transmission	Study[5]	and	was	calculated	using	
marginal	structural	modelling.	We	equated	the	OR	to	a	relative	risk	(RR)	for	this	analysis	as	the	
estimated	HIV	incidence	is	sufficiently	low.	Then	we	used	a	hypothetical	weak	estimate	of	
interaction	strength	(RR=1.2)	as	a	comparison.	The	additional	HIV	infections	per	year	attributable	to	
a	possible	IHC-HIV	interaction	are	estimated	as:	
	 (1)	
Parameter	definitions	for	all	equations	are	detailed	in	Box	1.	This	model	considers	HIV	acquisition	in	
women	only,	and	does	not	account	for	transmission	from	HIV-positive	women	to	uninfected	men.	
HIV	incidence	is	estimated	by	assuming	equilibrium	prevalence	and	a	mean	survival	time	with	HIV	
infection	of	ten	years	( ).	Full	derivations	for	all	equations	are	given	in	the	technical	
appendix.	
	Effects	of	reduced	IHC	use	on	live	births	and	maternal	deaths	per	year	
We	then	explore	the	impact	of	reducing	IHC	use	on	the	number	of	live	births	per	year.	This	statistic	is	
a	measure	of	the	potential	increase	in	unintended	pregnancies,	although	it	is	likely	to	be	an	
underestimation	as	it	does	not	capture	still-births,	spontaneous,	elective	or	therapeutic	abortions.	
We	simulate	a	scenario	whereby	all	IHC	use	is	stopped	and	IHC	replaced	for	some	women	with	a	
hypothetical	alternative	contraceptive	that	has	no	association	with	HIV	risk.	The	proportion	of	
women	transitioned	to	the	alternative	is	assumed	to	be	equal	to	the	proportion	of	non-IHC-using	
women	who	report	use	of	other	contraceptive	methods	to	reflect	the	current	availability	and	uptake	
of	other	contraceptive	methods	for	that	country[2];	the	remainder	are	assumed	to	stop	using	any	
form	of	contraception.	For	all	calculations	we	assume	that	IHC	has	a	failure	rate	of	6%	per	year	and	
85%	of	women	not	using	contraception	become	pregnant	within	one	year.[22]	The	alternative	
contraception	has	a	hypothetical	typical	failure	rate	of	12%	per	year,	which	is	the	mean	of	four	
common	non-IHC	contraceptive	methods	(both	modern	and	traditional):	male	condom,	18%;	
combined	oral	pill	(COC),	9%;	copper	intra-uterine	device	(IUD),	0.8%;	and	withdrawal,	22%	[22].	
Sensitivity	analyses	indicate	that	variations	in	this	assumption	have	a	limited	impact	on	the	
qualitative	results	(Supplementary	table	1).	All	pregnancies	are	assumed	to	result	in	live	births,	
which	may	be	an	overestimate	as	described	above.		
	
Under	these	conditions,	the	change	in	the	number	of	live	births	per	year	on	removal	of	IHC	is	given	
by:		
	 (2)	
	
	The	change	in	maternal	deaths	on	cessation	of	IHC	use	is	estimated	from	the	change	in	live	births,	
ΔB	(eq.	2),	using	the	per-country	maternal	mortality	ratio	(MMR)[24]:	
	 	 	 	 	 (3)	
The	MMR	represents	mortality	during	or	related	to	pregnancy,	child	birth	or	within	42	days	of	
termination	of	pregnancy[25]	so	will	capture	the	excess	maternal	mortality	related	to	unintended	
pregnancies	that	do	not	reach	full	term	as	well	as	those	that	result	in	live	births.	
	
Net	consequences	on	maternal	and	HIV-related	deaths	following	reduced	IHC	use	
To	explore	the	net	consequence	of	the	removal	of	IHC	from	family	planning	services,	we	calculated	
the	net	change	in	the	total	number	of	resulting	maternal	deaths	and	HIV-related	deaths.	An	excess	
infection	was	counted	as	an	additional	HIV-related	death	if	the	expected	timing	of	death,	after	
allowing	for	the	effects	of	antiretroviral	therapy	(ART),	was	before	the	estimate	of	life-
expectancy.[26]	ART	coverage	is	defined	by	country	for	low	and	middle	income	countries	where	data	
is	available,	else	a	regional	mean	is	assigned.[27,	28]	For	high	income	countries,	where	ART	coverage	
information	is	not	routinely	reported,	we	assume	a	high	coverage	of	80%.	The	mean	age	at	infection	
is	assumed	to	be	25	years	for	all	countries;	women	with	HIV	are	assumed	to	have	a	survival	time	of	
10	years	if	untreated,[29]	or	20	years	if	treated.[30,	31]	A	five	per-cent	discount	rate	per	year	of	
survival	post-infection	was	applied	to	all	HIV-related	deaths.	The	excess	number	of	HIV-related	
deaths	attributable	to	a	possible	IHC-HIV	interaction	is	given	by:	
	 (4)	
	
The	net	change	in	HIV-related	and	maternal	deaths	resulting	from	cessation	of	IHC	use	is	calculated	
by	subtracting	equation	(eq.)	4	from	eq.	3.	In	addition	to	the	two	estimates	for	the	strength	of	the	
interaction	between	IHC	and	HIV	risk	defined	above,	for	this	statistic	we	include	a	third	‘null’	
estimate	of	the	IHC-HIV	association,	where	we	assume	that	no	true	causal	relationship	exists	
between	IHC	and	risk	of	HIV	acquisition	(RR=1.0).	This	illustrates	the	public	health	outcomes	of	
reduced	IHC	use	if	there	is	no	true	biological	association.	
	
Results	
Distribution	of	injectable	hormonal	contraception	and	HIV	
Figure	1	charts	the	global	pattern	of	IHC	use	and	HIV	prevalence,	and	highlights	that	high	IHC	use	
coincides	with	high	HIV	prevalence	predominantly	in	southern	and	eastern	Africa.	The	generalised	
epidemic	in	this	region	means	that	many	women,	including	those	who	are	using	IHC,	may	be	
exposed	to	HIV.	Haiti	also	has	both	a	high	prevalence	of	IHC	use	and	a	high	prevalence	of	HIV.		
	
Effects	of	an	IHC–HIV	interaction	on	HIV	infections	per	year	
The	estimated	numbers	of	HIV	infections	in	a	country	that	could	be	attributed	to	IHC	use	under	two	
different	assumptions	about	the	IHC-HIV	interaction	are	shown	in	Figure	2A	(see	supplementary	
table	2	for	all	countries).	Globally,	a	total	of	27,000-130,000	infections	per	year	(for	RR=1.2-2.19)	
would	be	attributable	to	IHC,	87-88%	of	which	occur	in	southern	and	eastern	Africa.	For	example,	
13,000-59,000	HIV	infections	per	year	(5.4-25%	of	current	annual	infections	in	women	for	RR=1.2-
2.19,	data	not	shown)	in	South	Africa	may	be	attributable	to	IHC	use	and	2,900-14,000	(4.1-20%)	in	
Kenya.	
	
There	are	also	high	levels	of	excess	infections	relative	to	the	current	total	infections	in	Southeast	
Asia	(e.g.	Indonesia:	400-1,900	(6.0-27%);	Myanmar:	210-1,000	(3.8-19%))	and	some	Central	and	
South	American	countries	(Brazil:	170-1000	(0.79-4.5%);	Peru:	54-270	(3.5-18%)),	although	the	
absolute	number	of	excess	infections	is	low	everywhere	outside	of	Africa.	Countries	where	very	few	
infections	are	potentially	attributable	to	IHC	either	have	very	low	IHC	use	(India:	19-110	(0.02-
0.12%))	or	low	HIV	incidence	among	women	(USA:	61-360	(0.28-1.6%)).	These	excess	infections	
would	be	offset	by	a	17-54%	reduction	in	HIV	incidence	among	IHC	users	for	RR=1.2-2.19,	which	
could	be	mediated	by	increased	condom	use	or	ART	uptake	among	HIV-positive	partners	of	IHC	
users.		
	
Effects	of	reduced	IHC	use	on	live	births	and	maternal	deaths	per	year	
If	IHC	was	removed	and	only	partially	replaced	with	an	alternative	contraceptive,	there	would	be	an	
increase	in	the	number	of	live	births,	due	to	increased	numbers	of	unintended	pregnancies	(fig.	2B).	
These	would	be	substantial	in	countries	with	high	IHC	use	and	high	birth	rates;	primarily	in	southern	
and	eastern	Africa	(South	Africa:	360,000	extra	live	births	per	year	(34%	of	current	annual	live	
births);	Kenya:	300,000	(24%)),	South	and	South-East	Asia	(Bangladesh:	235,000	(6.5%);	Indonesia:	
1.8	million	per	year	(39%)),	and	Central	and	South	America	(Nicaragua:	30,000	(25%);	Peru:	92,000	
(18%)).	The	absolute	change	in	the	number	of	live	births	for	each	country	is	dependent	on	current	
IHC	use,[2]	population	size,[21]	birth	rate,[23]	and	the	reported	use	of	alternative	contraceptive	
methods,[2]	which	combine	to	give	the	largest	increase	in	live	births	for	Indonesia.	The	scale	of	the	
increased	numbers	of	live	births	following	reduced	IHC	use	is	much	greater	than	the	level	of	excess	
HIV	infections	if	IHC	use	continued.	
	
In	the	same	scenario,	these	unintended	pregnancies	are	accompanied	by	increases	in	maternal	
deaths	(fig.	2C),	particularly	in	countries	where	high	levels	of	IHC	use	coincide	with	a	high	MMR	
(Malawi:	2,500	extra	maternal	deaths	per	year	(36%	of	current	annual	maternal	deaths);	Ethiopia:	
1,500	(10%))	or	high	birth	rate	(Indonesia:	4,000	(39%);	Bangladesh:	780	(6.5%)).	
	
Net	consequences	on	maternal	and	HIV-related	deaths	following	reduced	IHC	use	
Figs.	3A	and	3B	show	the	direction	and	magnitude	of	the	net	change	in	HIV-related	and	maternal	
deaths	if	IHC	use	were	reduced,	under	different	assumptions	about	the	effect	size	of	an	IHC-HIV	
interaction.	
	
In	countries	where	the	decrease	in	HIV	incidence	outweighs	the	increase	in	maternal	deaths,	
irrespective	of	the	assumed	strength	of	the	IHC-HIV	association	(RR=1.2	or	2.19),	we	may	see	a	
reduction	in	total	deaths	on	cessation	of	IHC	use	(fig.	3A,	green).	These	are	mainly	limited	to	
southern	Africa,	with	the	largest	decrease	in	South	Africa	(5,100-27,000	fewer	deaths	per	year	(4.5-
24%	decrease	compared	to	total	expected	HIV-related	and	maternal	deaths	for	RR=1.2-2.19,	fig.	3B).	
	
There	is	a	wider	range	of	countries	where	the	net	effects	of	reducing	IHC	depends	strongly	on	the	
assumed	association	between	IHC	and	HIV	risk	(fig.	3A,	yellow):	if	there	is	a	strong	interaction	
(RR=2.19)	then	there	could	be	fewer	overall	deaths,	but	with	a	weaker	association	(RR=1.2)	there	
would	be	little	net	change	relative	to	the	current	number	of	HIV-related	and	maternal	deaths.	This	
includes	low	and	middle	income	countries	with	moderate	or	high	HIV	incidence	rates	(e.g.	Kenya:	
64–	5100	fewer	deaths	(-0.18	to	-14%);	Tanzania:	61	extra	–	2900	fewer	deaths	(+0.16	to	-7.4%))	and	
high	income	countries	with	low	maternal	mortality	where	any	decrease	in	HIV-related	deaths	
outweighs	increases	in	maternal	deaths	(USA:	17	–	140	fewer	deaths	(-0.18	to	-1.4%)).		
	
In	countries	where	maternal	mortality	is	high	compared	to	HIV	incidence,	reducing	IHC	use	would	be	
likely	to	increase	the	overall	deaths,	regardless	of	the	RR	estimate	used	(fig.	3A,	red).	This	includes	
areas	of	Central	and	South	America	(Nicaragua:	28	–	16	extra	deaths	(+14	to	+7.9%)),	West	and	
North	Africa	(Egypt:	46	–	6	extra	deaths	(+3.3	to	+0.46%)),	and	parts	of	Asia	(Indonesia:	3,000-3,800	
extra	deaths	(+28	to	+22%);	Bangladesh:	780	–	714	extra	deaths	(+5.9	to	+5.4%)),	with	the	maximum	
increase	in	Indonesia.	In	other	countries,	there	could	be	a	net	increase	in	deaths	following	reduction	
in	IHC	use,	depending	on	the	strength	of	the	IHC-HIV	association	(fig.	3A,	pink),	for	example	Malawi:	
1500	extra	-	2000	fewer	deaths	(+6.3	to	-8.2%);	Myanmar:	380	extra	–	75	fewer	deaths	(+7.2	to	-
1.5%).	
	
The	areas	where	there	is	little	change	in	net	maternal	and	AIDS-related	deaths	on	cessation	of	IHC	
(fig.	3A,	cream)	are	those	where	injectables	are	not	commonly	used	(India:	49-1	extra	deaths	(+0.090	
to	+0.00086%)).	
	
Fig.	3B	illustrates	the	potential	scale	of	the	changes	in	net	deaths	and	its	sensitivity	to	the	assumed	
IHC-HIV	interaction	strength.	Whilst	the	potential	reduction	in	deaths	resulting	from	reductions	in	
IHC	use	is	greatest	in	southern	Africa	with	the	higher	effect	estimate,	these	countries	would	also	see	
some	of	the	largest	increases	in	maternal	mortality	if	there	was	no	true	association	between	IHC	use	
and	HIV	risk	(RR	=	1).	Overall,	stopping	all	IHC	use	would	reduce	the	total	deaths	per	year	globally	by	
47,000	with	an	odds	ratio	of	2.19,	but	would	result	in	an	increase	of	3,400	deaths	with	the	more	
modest	estimate	of	1.2.	If	there	is	no	real	effect	of	IHC	on	HIV	acquisition	then	stopping	IHC	would	
cause	at	least	16,000	more	maternal	deaths	per	year	worldwide,	spread	primarily	through	Africa	and	
South	and	South-East	Asia	(fig.	3B).	
	
Sensitivity	analyses	show	that	varying	the	proportion	of	women	stopping	IHC	use	who	are	
transitioned	onto	the	background	established	mix	of	non-IHC	contraceptives	or	a	specified	
replacement	can	have	a	large	impact	on	the	change	in	net	deaths	in	countries	where	the	baseline	
level	of	IHC	replacement	is	very	low	(e.g.	Nigeria:	12%	transitioned	to	background	mix,	
Supplementary	Table	1)	or	very	high	(Brazil:	79%).	Reducing	HIV	incidence	among	IHC	users	also	has	
a	major	impact	on	net	deaths	by	reducing	HIV-related	deaths	without	increasing	maternal	deaths.	
Varying	the	assumed	background	or	replacement	contraceptive	efficacies	at	baseline	uptake	levels	
(which	are	generally	low)	has	a	limited	impact	on	model	outputs.		
	
Discussion	
High	IHC	use	and	high	HIV	prevalence	coincide	primarily	in	southern	and	eastern	Africa.	There	are	
over	ten	million	women	using	IHC	in	these	countries	who	are	therefore	at	a	potentially	elevated	risk	
of	HIV	acquisition,	or	if	IHC	use	was	reduced,	increased	unintended	pregnancy	and	maternal	death.	
	
If	the	association	between	use	of	injectables	and	HIV	acquisition	is	real,	a	reduction	in	IHC	use	is	
likely	to	reduce	HIV	infections	in	regions	of	high	incidence.	However,	where	MMR	is	also	high,	and	in	
the	absence	of	an	effective	alternative	contraceptive,	reductions	in	IHC	use	would	increase	
unintended	pregnancies	and	maternal	deaths.	The	direction	of	change	in	the	overall	number	of	
deaths	resulting	from	cessation	of	IHC	therefore	depends	on	the	relative	levels	of	HIV	incidence,	
birth	rate	and	MMR,	as	well	as	the	true	effect	size	of	the	interaction,	if	any.	In	countries	with	low	HIV	
incidence,	high	birth	rate	and	high	MMR,	such	as	Indonesia,	reducing	IHC	use	would	be	expected	to	
have	a	harmful	overall	effect;	whereas	for	countries	with	high	HIV	incidence	and	IHC	use,	such	as	
South	Africa,	reducing	IHC	could	lead	to	fewer	deaths	overall,	if	there	is	a	real	association	between	
IHC	and	HIV	acquisition.	For	countries	in	between	these	extremes,	the	overall	outcome	is	heavily	
dependent	on	the	magnitude	of	the	assumed	effect	size.	If	there	is	no	causal	link	between	IHC	and	
HIV	risk	(RR=1)	then	withdrawal	of	IHC	would	lead	to	an	increase	in	net	deaths	in	all	countries	(fig.	
3B).	
	
The	simple	metric	we	have	used	for	this	exploratory	analysis	is	based	on	only	two	outcomes	of	
reducing	IHC	use:	the	potential	decrease	in	HIV-related	deaths	due	to	a	reduction	in	infections,	and	
the	increase	in	maternal	deaths	due	to	additional	unintended	pregnancies.	It	does	not	account	for	
infant	deaths	or	the	broad	range	of	consequences	of	unintended	pregnancies	and	HIV	infection	for	
women	and	their	families.	The	wider	effects	of	HIV	infection	include	the	health	burden	of	HIV,	
reduced	ability	to	work	and	care	for	children	plus	the	associated	economic	costs,	possible	vertical	
transmission	and	social	stigma.	For	unintended	pregnancies,	as	well	as	the	pregnancy	itself,	other	
possible	outcomes	are	any	elective	or	spontaneous	abortions	–	which	have	important	implications	
for	morbidity	and	mortality	particularly	in	countries	where	safe	and	legal	abortion	services	are	not	
available,[32,	33]	complications	during	pregnancy	or	birth,	a	reduction	in	years	of	schooling	and	
consequent	loss	of	earning	potential,	the	economic	cost	of	interruption	to	employment	and	
childcare	costs.[34]		
	
We	have	modelled	a	hypothetical	scenario	where	there	is	no	replacement	contraceptive	as	effective	
as	IHC.	This	may	result	in	overestimation	of	the	increase	in	live	births	and	maternal	deaths	that	
would	occur	if	IHC	use	was	reduced.	If	a	practical,	effective	and	acceptable	alternative	contraception	
could	be	provided,	many	of	the	adverse	events	associated	with	unintended	pregnancies	would	be	
mitigated	and,	in	our	analysis,	the	relative	benefit	of	the	reduced	IHC	use	would	increase.	However,	
in	many	developing	countries,	in	practice	there	are	very	few	alternative	forms	of	contraception	
available	to	women.[35]		Conversely,	future	increases	in	ART	coverage	would	reduce	the	effective	
mortality	rate	of	HIV	by	extending	the	expected	survival	time,	as	defined	in	equation	(4).	However,	
this	model	does	not	capture	the	other	costs	and	morbidity	associated	with	HIV	infection	or	any	
reduction	in	overall	HIV	incidence	due	to	the	community-level	effects	of	increased	ART	coverage	on	
transmission,[36]	which	may	occur	to	some	extent	even	when	ART	is	used	along	current	
international	guidelines.[37,	38]	Our	method	also	overestimates	the	impact	of	reducing	IHC	use	on	
HIV	spread	in	countries	where	HIV	risk	is	limited	to	specific	sub-populations	who	may	not	be	the	
main	recipients	of	IHC.	
	
Furthermore,	cessation	of	IHC	use	has	been	applied	to	all	women	irrespective	of	HIV	status,	which	
may	increase	levels	of	perinatal	HIV	transmission	among	HIV-positive	women;	and	HIV	risk	has	been	
applied	to	all	women	homogeneously,	where	in	reality	graduations	in	risk	behaviour	will	affect	the	
apparent	overlap	between	use	of	injectables	and	risk	of	HIV	acquisition.	Further	analyses	are	needed	
to	incorporate	this	range	of	issues	in	a	full	exploration	of	the	aggregated	effects	and	the	wider	social	
impact	of	unintended	pregnancies	and	HIV	transmission.	There	are	also	potential	interactions	
between	the	two	outcomes.		There	is	mixed	evidence	with	respect	to	the	effect	of	pregnancy	on	HIV	
acquisition[8,	12-14]	and	one	study	that	indicates	that	pregnancy	increases	the	risk	of	
transmission[14];	and	reducing	IHC-related	HIV	infections	may	also	reduce	the	overall	MMR	in	some	
countries,[24]	which	could	partially	offset	increases	in	maternal	deaths	resulting	from	withdrawal	of	
IHC.	These	considerations	have	not	been	included	in	this	analysis	but	will	be	important	to	evaluate	in	
future	modelling	studies.	
	
We	have	limited	this	analysis	to	the	key	variables	affecting	HIV	acquisition	for	women	using	IHC	at	
present.	These	should	also	be	considered	in	the	context	of	future	changes	in	other	factors	affecting	
HIV	incidence	among	women	using	IHC,	for	example	increasing	dual	IHC	plus	condom	use	following	
the	recent	WHO	technical	statement	[15]	or	increasing	access	to	ART	among	HIV-positive	partners.	
The	decrease	in	incidence	required	to	offset	any	excess	risk	attached	to	IHC	use	increases	with	the	
strength	of	the	interaction	but	may	be	achievable	through	combination	of	multiple	prevention	
strategies.		
	
If	use	of	injectable	contraceptives	increases	HIV	acquisition	risk,	reducing	IHC	could	reduce	new	HIV	
infections,	but	this	must	be	balanced	against	important	other	consequences,	in	particular	increased	
unintended	pregnancies	and	maternal	deaths.		It	will	be	crucial	to	gain	a	clearer	understanding	of	
the	actual	interaction	between	IHC	and	HIV	but	unless	the	true	effect	size	approaches	the	higher	
reported	estimates,	it	is	unlikely	that	reductions	in	IHC	could	result	in	public	health	benefit,	with	the	
possible	exception	of	those	countries	in	southern	Africa	with	the	largest	HIV	epidemics.	
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Figure	legends	
Figure	1.	Prevalence	of	injectable	hormonal	contraceptive	(IHC)	use	and	HIV	prevalence	by	
country.	Countries	are	coloured	according	to	HIV	prevalence[16-20]	and	IHC	use[2]	among	15-49	
year-old	women:	red	=	high	IHC	and	high	HIV;	pink	=	high	IHC	and	low	HIV;	orange	=	low	IHC	and	
high	HIV;	yellow	=	low	IHC	and	low	HIV.	HIV	prevalence	above	1%	and	IHC	prevalence	in	the	top	
quartile	globally	are	defined	as	high	and	all	values	below	these	thresholds	are	low.	HIV	prevalence	
data	was	unavailable	for	15-49	year-old	women	in	Brazil,	China,	the	Democratic	Republic	of	the	
Congo	(DRC)	and	Thailand	therefore	we	use	reported	HIV	prevalence	from	antenatal	clinics	for	
Brazil,[17]	DRC,[19]	and	Thailand[20]	and	adult	HIV	prevalence	for	China.[18]		
	
Figure	2.	
A.	Excess	HIV	infections	per	year	attributable	to	a	hypothesised	IHC-HIV	interaction.	Countries	are	
ranked	according	to	the	total	number	of	HIV	infections	per	year	that	would	be	attributed	to	a	
putative	IHC-HIV	interaction	with	effect	size	(1)	RR=1.2	and	(2)	RR=2.19.[5]	The	ten	countries	with	
the	highest	excess	infections	are	shown	together	with	selected	examples	from	different	regions.	
Country	rankings	out	of	116	countries	with	available	data	are	annotated	next	to	the	respective	bars.	
Data	for	all	other	countries	can	be	found	in	supplementary	table	2	(online).	
B.	Excess	live	births	per	year	resulting	from	cessation	of	all	IHC	use;	and	
C.	Excess	maternal	deaths	per	year	resulting	from	cessation	of	all	IHC	use.	It	is	assumed	that	all	
women	previously	using	IHC	are	transitioned	to	either	no	contraception	or	a	hypothetical	
alternative,	in	proportion	to	the	method	mix	reported	by	the	non-IHC-using	population	for	each	
country.[2]	Countries	are	ranked	according	to	the	excess	number	of	live	births	per	year	that	can	be	
attributed	to	cessation	of	all	IHC	use.	The	ten	countries	with	the	highest	numbers	of	excess	births	
are	shown	together	with	the	examples	from	fig.	2A.	Country	rankings	out	of	134	countries	with	
available	data	are	annotated	next	to	the	relevant	bars.	Data	for	all	other	countries	can	be	found	in	
supplementary	table	2	(online).	
	
Figure	3.	Change	in	the	number	of	net	maternal	and	HIV-related	deaths	resulting	from	cessation	of	
IHC	use.		
A.	Direction	of	change.	Countries	are	coloured	according	to	the	direction	of	change	in	the	net	
number	of	maternal	and	HIV-related	deaths	that	result	directly	from	stopping	IHC	use	assuming	(1)	
RR=1.2	and	(2)	RR=2.19:	red	=	expected	increase	in	net	maternal	and	HIV-related	deaths	(>0.5%	
under	both	RR	assumptions);	pink	=	change	in	net	deaths	is	dependent	on	the	effect	size	(>0.5%	
increase	only	when	RR=1.2);	cream	=	reductions	in	IHC	use	unlikely	to	provide	public	health	benefit	
in	terms	of	deaths	prevented	(<0.5%	change		with	both	estimates);	yellow	=	change	in	net	deaths	is	
dependent	on	the	effect	size	(>0.5%	decrease	only	when	RR	=	2.19);	green	=	expected	decrease	in	
net	deaths	(>0.5%	under	both	RR	assumptions);	grey	=	data	not	available.	
B.	Absolute	change.	The	change	in	net	maternal	and	HIV-related	deaths	on	cessation	of	all	IHC	use,	
assuming	(1)	RR=1.0	(yellow),	(2)	RR=1.2	(light	blue)	and	(3)	RR=2.19	(dark	blue),	shown	for	the	
countries	presented	in	fig.	2.	Data	for	all	other	countries	can	be	found	in	supplementary	table	2	
(online).	
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